from,to,fromCount,edgewidth
Measures of coagulation (MC),ACT (OM),1,1
Need for further intervention (D 36),Adverse events (D36) (MC),1,1
Adverse events and effects (D 38),Adverse events (D38) (MC),1,1
Adverse events (D38) (MC),Adverse events (OM),1,1
Adverse events (CA),Adverse events and effects (D 38),1,1
Measures of coagulation (MC),aPTT (OM),1,1
Other laboratory measurements (D24) (MC),arterial blood gas (OM),1,1
Measures of coagulation (MC),ATIII (OM),1,1
Blood usage (MC),Avoidance of allogeneic transfusion (OM),1,1
Life impact (D25) (MC),Barthel Index (OM),1,1
Blood and lymphatic system outcomes (D 2),Bleeding (D2) (MC),1,1
Vascular outcomes (clinical) (D 24),Bleeding (D24) (MC),1,1
Bleeding (D24) (MC),Bleeding (OM),1,1
Physiological (CA),Blood and lymphatic system outcomes (D 2),1,1
Bleeding (D24) (MC),Blood loss (OM),1,1
Need for further intervention (D 36),Blood usage (MC),1,1
Bleeding (D24) (MC),Chest tube output (OM),1,1
Measures of coagulation (MC),Coagulation factors (OM),1,1
Other laboratory measurements (D24) (MC),Complement (OM),1,1
Other laboratory measurements (D24) (MC),Complete Blood Count (OM),1,1
Other (D32) (MC),Consented and received intervention (OM),1,1
Measures of coagulation (MC),Ddimers (OM),1,1
Mortality (MC),Death (OM),1,1
Life impact (CA),Delivery of care (D 32),1,1
Other (D32) (MC),Donor exposure (OM),1,1
Resource use (CA),Economic (D 34),1,1
Other (D34) (MC),Economic impact (OM),1,1
Other laboratory measurements (D24) (MC),Electrolytes (OM),1,1
Other laboratory measurements (D24) (MC),Endothelial markers (OM),1,1
Organ specific treatment effect (D17) (MC),Extended Glasgow Outcome Scale (OM),1,1
Delivery of care (D 32),Feasibility (MC),1,1
Feasibility (MC),Feasibility (OM),1,1
Blood usage (MC),FFP (OM),1,1
Measures of coagulation (MC),Fibrin monomer (OM),1,1
Measures of coagulation (MC),Fibrinogen (OM),1,1
Need for additional treatment (MC),Fluids (OM),1,1
Adverse events (D36) (MC),General (OM),1,1
Organ specific treatment effect (D17) (MC),Glascow Coma Scale (OM),1,1
Life impact (CA),Global quality of life (D 30),1,1
Other laboratory measurements (D24) (MC),HCT (OM),1,1
Need for additional treatment (MC),Hemostatic agents (OM),1,1
Bleeding (D2) (MC),Hemostatic efficacy (OM),1,1
Resource use (CA),Hospital (D 35),1,1
Physiological (CA),Immune system outcomes (D 11),1,1
Other laboratory measurements (D24) (MC),in vivo thrombin generation (OM),1,1
Other laboratory measurements (D11) (MC),Inflammation markers (OM),1,1
Measures of coagulation (MC),INR (OM),1,1
Organ specific treatment effect (D17) (MC),Intracerebral hemorrhage (OM),1,1
Length of stay (MC),Lenght of hospital stay (OM),1,1
Hospital (D 35),Length of stay (MC),1,1
Physical functioning (D 25),Life impact (D25) (MC),1,1
Global quality of life (D 30),Life impact (D30) (MC),1,1
Length of stay (MC),LOS Hospital (OM),1,1
Length of stay (MC),LOS ICU (OM),1,1
Length of stay (MC),LOS PICU (OM),1,1
Adverse events (D38) (MC),Lung injury (OM),1,1
Bleeding (D24) (MC),Major bleeding (OM),1,1
Blood and lymphatic system outcomes (D 2),Measures of coagulation (MC),1,1
Mortality and Survival (D 1),Mortality (MC),1,1
Mortality (MC),Mortality (OM),1,1
Mortality (MC),Mortality (OM),1,1
Death (CA),Mortality and Survival (D 1),1,1
Organ specific treatment effect (D17) (MC),mRS score (OM),1,1
Organ specific treatment effect (D17) (MC),National Institute of Health Stroke Scale (OM),1,1
Need for further intervention (D 36),Need for additional treatment (MC),1,1
Resource use (CA),Need for further intervention (D 36),1,1
Blood usage (MC),Need for massive transfusion (OM),1,1
Clinical (CA),Nervous system outcomes (D 17),1,1
Nervous system outcomes (D 17),Organ specific treatment effect (D17) (MC),1,1
Vascular outcomes (clinical) (D 24),Organ specific treatment effect (D24) (MC),1,1
Physical functioning (D 25),Organ specific treatment effect (D25) (MC),1,1
Delivery of care (D 32),Organ specific treatment effect (D32) (MC),1,1
Delivery of care (D 32),Other (D32) (MC),1,1
Economic (D 34),Other (D34) (MC),1,1
Measures of coagulation (MC),Other (OM),1,1
Immune system outcomes (D 11),Other laboratory measurements (D11) (MC),1,1
Blood and lymphatic system outcomes (D 2),Other laboratory measurements (D2) (MC),1,1
Respiratory thoracic and mediastinal outcomes (D 22),Other laboratory measurements (D22) (MC),1,1
Vascular outcomes (physiological) (D 24),Other laboratory measurements (D24) (MC),1,1
Life impact (CA),Physical functioning (D 25),1,1
Blood usage (MC),Plasma (OM),1,1
Measures of coagulation (MC),Plasma thromboplastin time (PTT) (OM),1,1
Blood usage (MC),plasma to crystalloid ratio (OM),1,1
Blood usage (MC),Platelets (OM),1,1
Measures of coagulation (MC),Protein C and S (OM),1,1
Measures of coagulation (MC),Prothrombin (OM),1,1
Other (D32) (MC),Protocol adherence (OM),1,1
Measures of coagulation (MC),PT (OM),1,1
Measures of coagulation (MC),PTT (OM),1,1
Adverse events (D38) (MC),Pulmonary oedema (OM),1,1
Life impact (D30) (MC),Quality of life (OM),1,1
Blood usage (MC),RBC (OM),1,1
Adverse events (D38) (MC),renal failure (OM),1,1
Adverse events (D38) (MC),Reoperation (OM),1,1
Other laboratory measurements (D24) (MC),Reptilase time (OM),1,1
Physiological (CA),Respiratory thoracic and mediastinal outcomes (D 22),1,1
Measures of coagulation (MC),Reversal of coagulopathy (OM),1,1
Adverse events (D38) (MC),safety (OM),1,1
Mortality (MC),Survival (OM),1,1
Measures of coagulation (MC),Thrombin generation (OM),1,1
Other laboratory measurements (D24) (MC),Thromboelastography (OM),1,1
Organ specific treatment effect (D32) (MC),Time from intervention to chest closure (OM),1,1
Feasibility (MC),Time to intervention (OM),1,1
Feasibility (MC),Time to RBCtransfusion (OM),1,1
Feasibility (MC),Time to transfuion (OM),1,1
Feasibility (MC),Traceability (OM),1,1
Adverse events (D38) (MC),Transfusion reaction (OM),1,1
Adverse events (D36) (MC),Urgent surgery (OM),1,1
Clinical (CA),Vascular outcomes (clinical) (D 24),1,1
Physiological (CA),Vascular outcomes (physiological) (D 24),1,1
Measures of coagulation (MC),Viscoelastic tests (OM),1,1
Blood usage (MC),Whole Blood (OM),1,1
